Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.98 CAD 1.54% Market Closed
Market Cap: 163.6m CAD

Cardiol Therapeutics Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cardiol Therapeutics Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Cash from Operating Activities
-CA$25.3m
CAGR 3-Years
0%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Cash from Operating Activities
-CA$165.8m
CAGR 3-Years
33%
CAGR 5-Years
26%
CAGR 10-Years
-51%
Aurora Cannabis Inc
TSX:ACB
Cash from Operating Activities
-CA$8.7m
CAGR 3-Years
53%
CAGR 5-Years
50%
CAGR 10-Years
-11%
Sundial Growers Inc
NASDAQ:SNDL
Cash from Operating Activities
CA$59.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Cash from Operating Activities
$19m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Cash from Operating Activities
CA$9.1m
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Cardiol Therapeutics Inc
Glance View

Market Cap
163.6m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
Not Available

See Also

What is Cardiol Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-25.3m CAD

Based on the financial report for Mar 31, 2025, Cardiol Therapeutics Inc's Cash from Operating Activities amounts to -25.3m CAD.

What is Cardiol Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-21%

Over the last year, the Cash from Operating Activities growth was -14%.

Back to Top